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Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged 
clinical course. Since this disorder is considered to be at increased risk of thromboembo-
lism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by 
use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized 
in the treatment of ET for the reduction of platelets. However, patients treated with ana-
grelide might experience cardiovascular adverse effects including myocardial infarction 
(MI), although these events are rare. Herein, we report a case of a 30-year-old female 
with well controlled ET by anagrelide, who eventually developed an acute non-ST ele-
vation myocardial infarction (MI). There has no found any cardiovascular risk factors in 
this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, 
cardiovascular function should be monitored in those patients prescribed with 
anagrelide.
Key Words Anagrelide, Essential thrombocythemia, Acute myocardial infarction
Correspondence to
Young Yiul Lee, M.D., Ph.D.
Division of Hematology/Oncology, 
Department of Internal Medicine, 
Hanyang University Hospital, 17, Haeng 
Dang-dong, Sung Dong-gu, Seoul 133-792, 
Korea
Tel: ＋82-2-290-8334
Fax: ＋82-2-298-9183
E-mail: leeyy@hanyang.ac.kr
Ⓒ2010 Korean Society of Hematology
INTRODUCTION
Essential thrombocythemia (ET), an acquired myeloproli-
ferative neoplasm, is characterized by excessive proliferation 
of megakaryocytes accompanied by persistent peripheral 
thrombocytosis [1]. Clinically, patients with ET develop 
thrombosis, hemorrhage, and microvascular complications. 
An increased number of circulating platelets is known to 
increase the risk of progression of these complications, as 
well as predispose the subject to thrombotic events. The 
main treatment strategy for ET is to rapidly decrease the 
patient’s platelet count to a normal level in order to prevent 
the development of ET-related complications. In addition, 
ideal therapeutic agents should have limited side effects and 
minimal long-term safety concerns. A number of therapeutic 
agents have been studied for the treatment of ET, including 
alkylating agents, hydroxyurea, and interferon-α [2, 3]. 
Recently, anagrelide has been introduced as a treatment for 
ET. Anagrelide is an oral imidazoquinazoline agent with 
a selective effect on the megakaryocyte cell lineage through 
the inhibition of cyclic-AMP phosphodiesterase III activity, 
which inhibits platelet aggregation [4, 5]. Use of anagrelide 
effectively decreases the incidence of thromboembolic and 
hemorrhagic events. However, it can also directly induce 
vasospasm of the coronary arteries, and can lead to other 
serious cardiovascular side effects, including congestive heart 
failure, arrhythmias, and acute coronary syndrome [6]. Acute 
coronary syndromes are reported in 1-5% of patients treated 
with anagrelide, although the overall incidence of acute coro-
nary syndromes is very rare [4, 7-9]. Here, we describe 
the case of a 30-year-old woman with ET who developed 
an acute, non-ST-segment elevation myocardial infarction 
(MI) with severe chest pain following the use of anagrelide. 
This patient had no cardiovascular risk factors, suggesting 
that anagrelide may have been the cause of her acute MI.Korean J Hematol 2010;45:136-8.
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Fig. 1. Initial electrocardiograph showing T-wave inversions in leads I, 
aVL, and V2 through V5, which are consistent with myocardial ischemia.
Fig. 2. Coronary angiography (CAG) and intravascular ultrasound (IVUS). (A) Left CAG before intracoronary nitroglycerin injection. (B) Left CAG
after intracoronary nitroglycerin injection. (C) Plaque rupture and thrombus formation in an IVUS image.
CASE REPORT
A 30-year-old female patient presented to the emergency 
department with dyspnea on exertion and severe left anterior 
chest pain that had begun about 30 minutes prior to arrival, 
and which increased in intensity over time. She reported 
a history of exertional chest pain that had begun 10 days 
prior to her presentation. Previous studies, including electro-
cardiography (ECG), cardiac biomarkers, echocardiography, 
and an exercise treadmill test had shown no abnormalities. 
Her chest pain had been slightly alleviated by sublingual 
nitroglycerine. The patient had no smoking history and had 
no cardiovascular risk factors such as hypertension, dyslipi-
demia, or diabetes mellitus. The patient had been diagnosed 
with ET 6 months previously at a workplace health screening, 
and was being treated with 100 mg aspirin, 500 mg hydrox-
yurea twice a day, and 1 mg anagrelide three times daily. 
Her ET was relatively well controlled without any other 
complications, and her platelet counts had been within the 
normal range. Initial vital signs were stable, with a blood 
pressure of 110/80 mmHg, a heart rate of 78 beats/min, 
and a respiratory rate of 18 breaths/min. S1 and S2 were 
normal and S4 was faintly audible at the apex. An ECG 
showed T-wave inversions in leads I, aVL, and in V2 through 
V5, which were consistent with myocardial ischemia (Fig. 
1). Neither cardiomegaly nor pulmonary congestion was not-
ed on a chest X-ray. The MB fraction of creatinine phosphoki-
nase (CK-MB) was 8.5 ng/mL and cardiac troponin I was 
3.08 ng/mL (upper normal limit, 0.07 ng/mL). B-type natriu-
retic peptide (100 pg/mL) was also slightly elevated. A com-
plete blood count showed the following: a leukocyte count 
of 3.70×10
3/μL, hemoglobin of 10.5 g/dL, and a platelet count 
of 388×10
3/μL. Low density lipoprotein (LDL) cholesterol 
level was 54 mg/dL. An echocardiograph revealed hypo-
kinesis in the anteroseptal wall and a left ventricular ejection 
fraction of 55%. These results were compatible with an acute, 
non-ST-elevation MI. Immediately, the patient was treated 
with anti-platelet therapy (300 mg aspirin and 600 mg clopi-
dogrel). In addition, according to the early invasive strategy, 
coronary angiography was performed, which revealed sig-
nificant segmental stenosis (90%) of the mid left anterior 
descending artery (LAD) (Fig. 2A). The segmental lesion 
in the mid LAD did not respond to intracoronary nitro-
glycerin injection, which excluded coronary spasms as the 
causative factor (Fig. 2B). An intravascular ultrasound (IVUS) 
scan showed a focal soft plaque with a ruptured cap and 
thrombus formation (Fig. 2C). Percutaneous coronary angio-
plasty and stenting (Promus, 3.5×18 mm) were performed 
successfully. After coronary angioplasty, the chest pain and 
T-wave inversions on ECG disappeared. Anagrelide was dis-
continued, anti-platelet and anti-anginal agents were added 
to the treatment, and the patient was discharged without 
further cardiac symptoms.
DISCUSSION
　ET is a myeloproliferative neoplasm with a chronic clinical 
course [1]. Patients with ET may experience thromboembolic 
episodes and, less frequently, hemorrhagic events. If an effec-
tive cytoreductive therapy is not introduced, acute coronary Korean J Hematol 2010;45:136-8.
138 Young-Hyo Lim, et al. 
syndromes resulting from coronary artery involvement may 
develop in patients with ET. However, case reports of MIs 
in well-controlled cases of ET are rare, and most reports 
are of elderly subjects with various cardiovascular risk factors 
[7, 10, 11]. Our patient was a young woman with no smoking 
history and without hypertension, dyslipidemia, diabetes 
mellitus, or obesity. Although the patient had an underlying 
disease, ET, the disease was well controlled and she had 
a normal platelet count. Considering that the risk of throm-
botic events decreases in patients with ET who have lower 
platelet counts, we tentatively suggest the possibility that 
anagrelide was the cause of the acute MI in this patient.
  The most common side effects of anagrelide are headache, 
nausea, diarrhea, edema, palpitations, and an increased num-
ber of myocardial contractions [4, 9]. Potential cardiovascular 
adverse effects include vasospasm of the coronary arteries, 
congestive heart failure, arrhythmia, or acute coronary syn-
drome [4, 6, 8]. In addition, myocarditis, silent MI, and 
myocardial ischemia have been reported in young patients 
with ET and without cardiovascular risk factors following 
the administration of anagrelide [4]. Although a clear correla-
tion between the administration of anagrelide and these 
events has not been well established, studies demonstrate 
that the adverse events disappear after anagrelide is dis-
continued [4]. In this patient, the segmental stenotic lesion 
in the mid LAD did not respond to an intracoronary nitro-
glyceride injection; thus, we can exclude the possibility of 
a vasospasm. According to the patient’s coronary angiography 
and IVUS, a stenotic lesion within the mid LAD resulted 
from a plaque rupture followed by thrombus formation. 
Furthermore, after percutaneous coronary intervention with 
stent insertion, the patient’s chest pain and T-wave inversions 
on ECG disappeared. Although MI is a rare event among 
ET patients treated with anagrelide, it may be an important 
and undesirable effect of anagrelide. The mechanism of acute 
coronary syndrome in patients treated with anagrelide has 
been reported to result from vasospasms of the coronary 
arteries [8], although this could not be fully elucidated in 
the present case. Close monitoring and prompt reporting 
of adverse events in clinical practice are important, as they 
may provide clues as to the mechanism of these undesirable 
side effects. It has been suggested that the majority of the 
side effects of anagrelide might develop within 1 month 
of starting therapy, and that the side effects are dose-depend-
ent [12-14]. Although the reduction of side effects might 
be related to improved tolerance to treatment over time, 
anagrelide should be discontinued in patients who experience 
life-threatening adverse events, such as acute coronary syn-
dromes [4, 8, 9].
  We treated an acute MI in a young female patient with 
ET who had no cardiovascular risk factors and no history 
of thrombotic events prior to taking anagrelide. Anagrelide 
is a useful drug for the treatment of ET; however, through 
this case we emphasize the importance of monitoring car-
diovascular function both before starting therapy and during 
the maintenance of treatment. For young patients with ET 
who have a long life expectancy, the long-term benefits 
from discontinuing anagrelide should be weighed against 
the potential cardiovascular risks posed by uncontrolled ET. 
Finally, it is probable that combining anagrelide with an-
ti-platelet drugs in patients with ET might be useful, as 
this might allow for a reduction in the dose of anagrelide, 
which would result in fewer side effects. For improved pro-
tection against acute coronary syndrome, it is imperative 
that anti-platelet drugs are added to anagrelide regimens 
in patients with ET who have cardiovascular risk factors.
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